Obesity Drugs in Development: 87 Trial Records for 14 Programs

By the WPG Research Team · Updated September 2026

This tracker covers 14 selected obesity drugs in development and 87 Phase 3 trial records, checked September 29, 2026. Only CagriSema in this selected set has a documented FDA filing. Weight Loss Provider Guide’s registry review found 38 records marked recruiting. The full table, sources and free CSV are below.

Key obesity drug pipeline statistics (September 2026)

1. 14 selected drug or combination programs appear in Weight Loss Provider Guide’s September 29, 2026 tracker. Each has Phase 3 records or an FDA filing; this is not a count of the whole pipeline (program table).
   Copy statisticCopy citationCopy section URL
2. 1 of the 14 has a documented FDA filing: Novo Nordisk filed CagriSema on December 18, 2025. Its September 21, 2026 update forecast an FDA decision in Q4 2026; that is a company forecast, not approval (Novo Nordisk).
   Copy statisticCopy citationCopy section URL
3. Q1 2027: Eli Lilly plans to submit retatrutide to the FDA in the first quarter of 2027 (Eli Lilly, July 23, 2026).
   Copy statisticCopy citationCopy section URL
4. 38 of 87 matched Phase 3 trial records listed “recruiting” on September 29, 2026, in Weight Loss Provider Guide’s review of ClinicalTrials.gov (status table; records).
   Copy statisticCopy citationCopy section URL
5. 10 of the 14 programs had at least one matched Phase 3 record listed as recruiting on September 29, 2026, in Weight Loss Provider Guide’s registry review (program table).
   Copy statisticCopy citationCopy section URL
6. 5 of the 14 programs act on amylin receptors: CagriSema, zenagamtide, cagrilintide, eloralintide and petrelintide. None of these five had FDA weight-management approval in the September 29, 2026 sources checked (mechanisms; sources).
   Copy statisticCopy citationCopy section URL
7. 11 of the 14 programs act on at least one target besides GLP-1, and 3 do not act on GLP-1 at all, according to Weight Loss Provider Guide’s classification of the selected programs on September 29, 2026 (mechanisms).
   Copy statisticCopy citationCopy section URL
8. 4 of the 14 programs have an oral Phase 3 record in this registry: aleniglipron, elecoglipron, zenagamtide and ribupatide. Ribupatide’s oral record is a China trial, not its planned global oral program (pill table; checked September 29, 2026).
   Copy statisticCopy citationCopy section URL
9. 2 of the 14 programs test roughly monthly injections: MariTide and berobenatide. Schedules differ by study (Amgen; Pfizer; checked September 29, 2026).
   Copy statisticCopy citationCopy section URL
10. 28.3%: retatrutide’s highest studied dose produced 28.3% average weight loss at 80 weeks in TRIUMPH-1 under the efficacy analysis, or 25.0% under the treatment-regimen analysis. This is a selected trial result, not a cross-trial record (Lilly, May 21, 2026).
    Copy statisticCopy citationCopy section URL
11. 37 of 69 ongoing or planned records with estimated primary completion dates list 2028, in Weight Loss Provider Guide’s September 29, 2026 registry review. These are dates for collecting primary-outcome data, not result releases or approvals (date table).
    Copy statisticCopy citationCopy section URL
12. 13 to 200+: the seven selected publisher counts in Weight Loss Provider Guide’s September 2026 comparison range from 13 to more than 200. Their scopes differ; paid underlying lists were not independently recounted (count audit).
    Copy statisticCopy citationCopy section URL
13. September 22, 2026: Zealand Pharma announced petrelintide’s Phase 3 program initiation. The three matched records still listed “not yet recruiting” in their September 28 updates (Zealand; records).
    Copy statisticCopy citationCopy section URL
14. 100 days apart: the FDA approved the Wegovy pill on December 22, 2025, and Foundayo on April 1, 2026—the first two oral GLP-1 medicines for weight loss (Novo Nordisk; FDA).
    Copy statisticCopy citationCopy section URL

On this page: The 14 drugs · How many are in development · When they could be approved · Reported weight loss · What's different · Pills and monthly shots · Recruiting trials · Names and counts · What changed · Can I get them now? · Method · Cite · Download · FAQ · Sources

Which obesity drugs are in late-stage development?

The 14 selected programs have 87 matched Phase 3 records. One has a documented FDA filing. Four others have reported Phase 3 obesity results, eight have Phase 3 trials running, and one has an announced start with records still marked “not yet recruiting.”

A “program” here means one drug or fixed combination; it can have several trials. The FDA is the U.S. Food and Drug Administration. Phase 3 tests a drug in larger groups before an approval decision. Think of it like a final exam, but a program can have several exams running at once. CagriSema has submitted an FDA application. A reported result does not mean every trial for that drug has ended (FDA).

Source: Weight Loss Provider Guide Research, obesity drug pipeline tracker, checked September 29, 2026. Stages come from company announcements; trial records from ClinicalTrials.gov. "Records (recruiting)" counts the Phase 3 obesity trial records we matched to each drug and how many listed "recruiting."

Our counting rule

This is a selected reference, not an exhaustive screen of every obesity program. We checked the 14 named programs against these rules:

1. The FDA has not approved it for chronic weight management.
2. Its maker announced Phase 3 initiation in adults with obesity or overweight, a Phase 3 record is registered, or the maker has filed it with the FDA. A registered study that has not opened is labeled separately.
3. It's one drug or one fixed combination. A pill and a shot of the same drug share one row.

The watchlist gives separate examples of planned formulations, region-specific approvals and rare-obesity programs. Approval outside the U.S. does not by itself determine inclusion. We include China trials for ribupatide, so this is not a U.S.-only trial list.

How many obesity drugs are in development?

It depends on what you count. The published counts below run from 13 to more than 200. Some cover broad pipelines; others list a handful to watch. Our 14 is the size of a selected reference, not a worldwide total or a count of drugs certain to reach pharmacies.

Source: each publisher, linked; compiled by Weight Loss Provider Guide Research, checked September 29, 2026.

These figures are not a like-for-like comparison. We verified what each public page says, not the contents of paid reports. A “200+” claim is a lower bound, not an exact count, and none of these counts tells us how many drugs will reach a pharmacy in the next few years.

Why two short lists don't match

Becker's list and ours are almost the same size, 13 and 14. They share only 9 drugs.

Becker's includes four drugs outside our selected list: APHD-012 (Phase 2 work reported by Aphaia), ARD-101 (its HERO trial ended), and ecnoglutide and mazdutide (China approvals). Ours includes five it leaves out: cagrilintide, elecoglipron, enicepatide, ribupatide and petrelintide.

Same size, different drugs. That's why a count needs its rule printed next to it.

When will the new obesity drugs be approved?

The sources checked do not establish a confirmed FDA approval date for any of the 14. Novo forecast a Q4 2026 decision on CagriSema; Lilly plans a retatrutide filing in Q1 2027. These are company plans, not approved launch dates (Novo; Lilly).

Source: company announcements and ClinicalTrials.gov, linked in Table 1 and the dataset; checked September 29, 2026. "Estimated" dates come from the trial record and can move.

What the trial dates mean

A trial's "primary completion date" is when it finishes collecting data for its main question. It is not a launch date or a promise of when results will be published. Results, an FDA application and an approval decision are separate steps; follow-up studies can continue during review (ClinicalTrials.gov; FDA).

Of the 70 ongoing or planned Phase 3 records we matched, 69 list an estimated primary completion date. Thirty-seven of them, a little over half, point to 2028.

Source: ClinicalTrials.gov records compiled by Weight Loss Provider Guide Research, checked September 29, 2026. Of the 70 ongoing or planned records, 1 lists an actual primary completion date that has already passed. None has a blank primary completion date in this snapshot.

What "Phase 3," "filed" and "approved" mean

• Phase 3: large trials, often with thousands of people, that test whether a drug works and is safe enough to approve.
• Filed: the company has sent the FDA its full application. Filing is not approval.
• Approved: the FDA has said yes for a specific use. Approval of a drug, trial access and a clinician’s prescribing decisions are different things.

Why a trial can stay "active" after its main results

Some trials keep going after the main question is answered. CagriSema's REDEFINE 1 record lists an actual primary completion date in October 2024 but was still "active, not recruiting" on September 29, 2026, because it includes an extension (ClinicalTrials.gov NCT05567796).

How much weight do the new drugs help people lose?

Retatrutide produced 28.3% average weight loss at 80 weeks in TRIUMPH-1 under the efficacy analysis, or 25.0% under the treatment-regimen analysis, Lilly reported. This is one selected result, not the highest result across every study or extension. The trials below differ in length, dose and who took part, so these numbers are not a ranking.

Here's what 28.3% looks like. People in TRIUMPH-1 started at about 248 pounds on average. On the top dose, they lost about 70 pounds (Eli Lilly).

Source: each company's release, linked. Compiled by Weight Loss Provider Guide Research, checked September 29, 2026. Results come from different trials, lengths, doses and groups of people. “Placebo-adjusted” means the difference between treatment and placebo, in percentage points—not a relative percent improvement. Most rows are absolute body-weight loss; the berobenatide and enicepatide rows are adjusted differences. “Not shown” means not transcribed from the linked release, not absent from all trial reports.

Petrelintide’s result release was posted September 29, 2026 U.S. time and is datelined September 30 in Denmark; the source date is not silently changed.

Rounding in the source: Structure reports 15.3% loss versus 1.1% gain and a placebo-adjusted difference of 16.3 percentage points. Subtracting the displayed rounded values gives 16.4. We keep the reported 16.3 and show the mismatch rather than silently change the source (Structure).

Different time, different group: Lilly also reported 30.3% at 104 weeks in a selected TRIUMPH-1 extension. It included people with a starting BMI of at least 35 who completed the main study and tolerated treatment. That is not the full 80-week study population (Lilly).

You can read more about retatrutide's trial results and side effects, or see how retatrutide compares with tirzepatide, which is already approved.

Why the same trial has two weight-loss numbers

Many trials report two answers. An estimand is the treatment-effect question an analysis is designed to answer. The details vary by trial.

• "If everyone had stayed on the drug" (the efficacy estimand). This estimates the result under continued treatment and the study’s other rules; it is not simply an average of people who finished.
• "Counting everyone assigned the drug" (the treatment-regimen or treatment-policy estimand). This estimates the effect regardless of treatment adherence, using the study’s rules for missing data and other treatments.

Take retatrutide's TRIUMPH-4 trial. On the 12 mg dose at 68 weeks, Lilly reported 28.7% weight loss the first way and 23.7% the second way (Eli Lilly). That's a gap of 5.0 percentage points. Same drug, same trial, same people. Just two different questions.

When quoting a result, name the trial, group, duration and analysis. Show both estimates when the difference matters. Neither should be renamed a “real-world” result.

What's different about the new obesity drugs?

Eleven of the 14 act on something besides GLP-1 (glucagon-like peptide-1), the gut hormone whose action Wegovy mimics. Five act on amylin receptors, which help signal fullness. Three skip GLP-1 entirely (mechanism sources).

Source: Weight Loss Provider Guide Research classification of Lilly, Novo, Amgen, Viking, Structure, AstraZeneca, Pfizer, Roche, Kailera, Zealand and cagrilintide receptor research; checked September 29, 2026. Cagrilintide also acts at calcitonin receptors; “amylin-based” does not mean an exclusive receptor target.

Amylin: the fullness hormone behind 5 of the 14

Your pancreas releases amylin with insulin after you eat. It helps tell your brain you’re full (Lilly; receptor research). Five of the selected programs act on amylin receptors. Two mix that action with GLP-1 (CagriSema and zenagamtide). Three are amylin-based without GLP-1 (eloralintide, cagrilintide and petrelintide). Cagrilintide also has calcitonin-receptor activity.

None of these five programs had FDA weight-management approval in the sources checked. Novo describes CagriSema as a proposed first combination of a GLP-1 medicine and an amylin analogue for weight management (Novo Nordisk).

GIP and glucagon

GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone. Zepbound, which is already approved, works on both GIP and GLP-1. Three drugs on this list do the same: VK2735, enicepatide and ribupatide.

Glucagon is a hormone that helps the body burn stored energy. Survodutide pairs it with GLP-1. Retatrutide works on all three: GIP, GLP-1 and glucagon.

The one that blocks instead of boosts

MariTide is the odd one out. It turns GLP-1 on but blocks the GIP receptor. It's also built to be given about once a month instead of once a week (Amgen).

Are new weight-loss pills and monthly shots coming?

Four of the selected programs have an oral Phase 3 example: aleniglipron, elecoglipron, zenagamtide and ribupatide. Two also test roughly monthly shots: MariTide and berobenatide. The sources checked do not establish an FDA filing for any of these six programs.

Source: company announcements and ClinicalTrials.gov records, checked September 29, 2026.

Two oral GLP-1 medicines are already FDA-approved for weight loss: the Wegovy pill, approved December 22, 2025, and Foundayo, approved April 1, 2026. Those approvals were 100 days apart. Other kinds of weight-loss pills existed before them (Novo Nordisk; FDA).

A pill and a shot of the same drug can be at different stages. Viking's VK2735 shot is in Phase 3, but Viking expects to start Phase 3 for its pill in the fourth quarter of 2026 (Viking Therapeutics). So "VK2735 is in Phase 3" is true only for the shot.

Ribupatide’s China tablet record is already Phase 3. Kailera’s separate plan for global oral Phase 3 trials as early as the first half of 2027 does not erase that China record (registry; Kailera).

For pills you can get now, see our look at oral GLP-1 options and where oral tirzepatide stands.

Which Phase 3 obesity trials are recruiting?

Of the 87 Phase 3 records matched to the 14 selected programs, 38 listed “recruiting” on ClinicalTrials.gov on September 29, 2026. Another 22 were active but not recruiting, 10 had not opened, 16 were completed and 1 was withdrawn. Ten of the 14 programs had at least one recruiting record.

Source: ClinicalTrials.gov records compiled by Weight Loss Provider Guide Research, checked September 29, 2026.

Four selected programs had no recruiting record in this query on the check date: retatrutide, survodutide, the VK2735 shot and petrelintide. Petrelintide’s matched records were registered but had not opened. This does not establish that no other recruiting trial exists outside the query.

"Recruiting" is a starting point, not a promise. It doesn't mean a site near you has room, or that you qualify. The study record lists the sites and the rules.

Look up a drug or trial

Type a drug name, an old code name or a trial number (it starts with "NCT"). You can also filter by status, drug or year. The full table below works without the search box.

Source: ClinicalTrials.gov, one row per record, linked; compiled by Weight Loss Provider Guide Research, checked September 29, 2026. "Est." = estimated; "Act." = actual. Enrollment is the record's own number and can include people counted in another record (extensions), so don't add them up.

Why do drug names and counts get mixed up?

One drug can have three or four names, and one trial record can cover two drugs or two studies. That's how the same pipeline turns into different counts. Here's the name key.

Source: company releases and ClinicalTrials.gov records linked in Table 1 and the dataset; checked September 29, 2026.

Amycretin and zenagamtide are the same drug

Novo Nordisk renamed amycretin as zenagamtide. Count it once. One of its Phase 3 trials, AMAZE 1, is filed under the code NNC0487-0111, so a search for "zenagamtide" alone can miss it (ClinicalTrials.gov NCT07339423).

One record, two drugs

One trial in children and teens tests both CagriSema and cagrilintide (NCT07253285). It shows up under both drugs. In any total, it counts once. REDEFINE 1 also has separate CagriSema and cagrilintide-alone arms (NCT05567796). Both records count under both programs, but each counts once in the registry total. That is why the program counts add up to 89 memberships, while the registry has 87 unique records.

One record, two studies

AstraZeneca's EMBOLD record covers two separate main studies under one number (NCT07667803). So 87 records is not the same as 87 separate studies.

What changed in the obesity pipeline in the past year?

The FDA approved two oral GLP-1 medicines for weight loss, a higher-dose Wegovy shot and a new use for Imcivree between December 2025 and April 2026. CagriSema was filed, and Zealand announced petrelintide’s Phase 3 initiation on September 22, 2026. These changes matter because older lists can mix approved drugs with experimental ones.

Source: each company or the FDA-approval announcement, linked; compiled by Weight Loss Provider Guide Research, checked September 29, 2026.

Related developments and formulations to watch

Source: company announcements and the Aardvark SEC filing, linked; checked September 29, 2026. Planned windows are not completed milestones.

Can I get these drugs now?

None of these 14 selected programs had FDA weight-management approval in the sources checked. Trial participation is not the same as routine prescribing. FDA also has an expanded-access pathway for some people with serious conditions when no satisfactory alternative is available; that requires separate medical and regulatory review and does not establish access to a particular drug (FDA).

A product sold online as “retatrutide” is not an FDA-approved retatrutide medicine. The drug name on an offer does not establish approval, quality or trial access.

To ask about joining a study, open a trial number from Table 9 on ClinicalTrials.gov and look for sites marked "recruiting" near you. The study team decides who qualifies.

If you'd rather start with something approved now, here are current self-pay prices for the Wegovy pill, Foundayo and other brand-name GLP-1s. Our GLP-1 Telehealth Pricing Index tracks what online programs charge.

How we built this tracker

Drug list. On September 29, 2026, we reviewed the 14 selected drug or combination programs in this reference against company releases, investor reports, SEC filings and trial records. We checked each program’s reported stage, names, target and form. We checked approval announcements separately. This was not an exhaustive search for every candidate worldwide. A program can have trials in several countries; “not FDA-approved” describes its U.S. weight-management status, not the location of every trial.

Trial records. We retrieved Phase 3 records from the ClinicalTrials.gov v2 API on September 29, 2026. The expanded name-and-code query returned 87 records. A separate identifiers-only pull also returned the same 87 NCT numbers; there was no next-page token. We kept one row per NCT number and copied each record’s status, primary completion date, date type, enrollment and last update as listed.

The query uses query.cond=obesity, filter.advanced=AREA[Phase]PHASE3, pageSize=100, countTotal=true and the following intervention names and codes:

CagriSema OR retatrutide OR LY3437943 OR cagrilintide OR NNC0174-0833 OR survodutide OR "BI 456906" OR maridebart OR "AMG 133" OR VK2735 OR petrelintide OR ZP8396 OR RO7895515 OR eloralintide OR LY3841136 OR zenagamtide OR amycretin OR NNC0487-0111 OR NN9487 OR CT-388 OR enicepatide OR RO7795068 OR RG6640 OR aleniglipron OR GSBR-1290 OR elecoglipron OR AZD5004 OR ECC5004 OR berobenatide OR PF-08653944 OR MET-097i OR MET-097 OR ribupatide OR KAI-9531 OR HRS9531

Run the exact registry query. The 87-record snapshot is preserved in the CSV; a live rerun can return later changes.

Checks. Every record’s core fields were checked in the live API response. We read descriptions and intervention details more closely where they affected a public claim: the two shared CagriSema/cagrilintide records, the China oral ribupatide record and the EMBOLD master protocol. We separately checked the dated start milestones shown here. This does not mean every field in every full protocol received a second-source review. A blank or “not checked” detail in our download is not a claim that the registry lacks that detail.

Counting. We count NCT identifiers, not patients or independent studies. Two records have separate CagriSema and cagrilintide-alone arms, so 89 program memberships become 87 unique records. “Ongoing or planned” includes recruiting, active/not recruiting and not yet recruiting: 38 + 22 + 10 = 70. Of those, 69 have estimated primary completion dates and one has an actual date. We group estimated dates by their recorded year and keep the source’s day or month precision.

Source differences. The registry and a company announcement can report different enrollment figures. We preserve the registry number in the CSV and show the company figure separately; the sources checked do not resolve these differences:

• Trial: TRIUMPH-1
  • Registry field checked September 29, 2026: 2,335, actual enrollment
  • Company announcement: 2,339 randomized
  • Sources: Registry; Lilly, May 21, 2026
• Trial: TRIUMPH-3
  • Registry field checked September 29, 2026: 1,946, actual enrollment
  • Company announcement: 1,949 randomized
  • Sources: Registry; Lilly, July 23, 2026
• Trial: REDEFINE 1
  • Registry field checked September 29, 2026: 3,400, estimated enrollment
  • Company announcement: 3,417 randomized
  • Sources: Registry; Novo, December 20, 2024

Results and publisher counts. Trial results come from the named company or its filing, with the trial, duration and analysis kept together. We did not calculate a pooled weight-loss result. The count audit checks what each public publisher page says; it does not verify the contents of paid pipeline reports. Those reported counts are not inputs to our 14-program or 87-record totals.

To reproduce it: use the exact API query, compare its returned NCT identifiers with the trial CSV, then filter by the status and date-type fields described above. Live results can change. The dated CSV preserves the values used for this page; a later query is a later snapshot, not proof of a change on September 29.

What we excluded: records outside the disclosed Phase 3 query and programs outside the selected 14. The matched records include multinational, pediatric, extension, cardiovascular, sleep-apnea and other obesity-related studies—not only adult weight-loss efficacy trials. We do not add separate program rows for a pill and shot of the same drug. Regional approvals and additional programs are discussed separately where useful.

What this data shows, and what it doesn't

It shows a dated reference for 14 selected programs: their reported stages, targets, forms, selected trial results and 87 matched Phase 3 registry records. It does not establish that these are all the programs meeting those broad criteria.

It doesn't show which drug works best (no trial here compares them all), when any drug will launch, what any drug will cost, whether insurance will cover it, or whether it's right for you. It's not a count of every obesity drug worldwide. A search can miss a record filed under an unexpected name. Registry fields come from the trial sponsors and can lag.

This is general information, not medical advice. Talk with a licensed clinician about weight-loss treatment.

How to cite this page

WPG Research Team. “Obesity Drugs in Development: 87 Trial Records for 14 Programs.” Weight Loss Provider Guide. Data checked September 29, 2026. https://weightlossproviderguide.com/research/obesity-drug-pipeline. Accessed [insert access date].

Reuse: Our original compilation and charts may be reused under CC BY 4.0 to the extent we own or may license them; credit Weight Loss Provider Guide Research for that contribution and preserve the underlying sources’ attribution and terms. No link is required.

Download the data

Four free CSV files. No sign-up, no email. Every row carries its source link and check date.

• Late-stage drugs: obesity-drugs-late-stage-2026-09-29.csv (14 rows)
• Phase 3 trial records: obesity-drug-phase3-trial-records-2026-09-29.csv (87 rows)
• Count audit: obesity-pipeline-count-audit-2026-09-29.csv (7 rows)
• Changes and watchlist: obesity-pipeline-changes-and-watchlist-2026-09-29.csv (17 rows)

Frequently asked questions

What new weight-loss drugs are coming in 2026?

CagriSema is the one program in this selected set with a documented FDA filing. Novo’s September 21 update forecast a decision in Q4 2026, not a guaranteed launch. Two oral GLP-1 medicines for weight loss were already approved: the Wegovy pill on December 22, 2025, and Foundayo on April 1, 2026 (Novo; approval dates).

When will retatrutide be released in the USA?

The sources checked do not establish a confirmed U.S. release date. Lilly plans an FDA submission in Q1 2027; a submission is not approval (Lilly, July 23, 2026). Trial access and any separately authorized expanded access are not routine commercial availability (FDA).

What is the newest medication for obesity?

Foundayo (orforglipron) is the new active drug in the approval events covered here: FDA approved it on April 1, 2026 (FDA). FDA also approved higher-dose Wegovy and a new Imcivree use for acquired hypothalamic obesity on March 19, 2026. A new drug, a new dose and a new use are different types of approval (approval table).

How many obesity drugs are in development?

The selected publisher counts range from 13 to more than 200, but their scopes differ. Our tracker covers 14 selected programs and 87 matched Phase 3 records as of September 29, 2026—not the whole global pipeline (count audit; method).

Is there a new weight-loss pill coming?

Four programs in this reference have an oral Phase 3 record: aleniglipron, elecoglipron, zenagamtide and ribupatide; ribupatide’s tablet trial is in China (pill table). Viking’s July 29, 2026 update planned oral VK2735 Phase 3 for Q4 2026 (Viking). A company plan is not a completed start.

What obesity drugs does Eli Lilly have in the pipeline?

Two are on this list: retatrutide, with Phase 3 results and a planned Q1 2027 FDA filing, and eloralintide, with Phase 3 records (Lilly; ENLIGHTEN-1). This is not a complete list of Lilly’s research programs. Zepbound and Foundayo are already approved products, not part of this selected first-approval pipeline (Lilly).

Are amycretin and zenagamtide the same drug?

Yes. Zenagamtide is the newer name for amycretin, so count it once. Some trial records use its code, NNC0487-0111 (Novo Nordisk; AMAZE 1).

Can I join a trial marked "recruiting"?

Maybe. Thirty-eight of the 87 matched Phase 3 records listed “recruiting” on September 29, 2026, but each study has its own sites and rules (records). Open the record on ClinicalTrials.gov to find sites and contacts; the study team decides who qualifies.

Why do reports give two weight-loss numbers for the same drug?

A trial may estimate both continued-treatment and treatment-policy effects, using its rules for missing data and other treatments. Retatrutide’s TRIUMPH-4 study reported 28.7% and 23.7% for its 12 mg arm at 68 weeks—a 5.0-percentage-point gap, not a 5% relative gap (Lilly).

What is amylin?

Amylin is a hormone your pancreas releases with insulin after meals; it helps you feel full. Five of the 14 selected programs act on amylin receptors. None of those five had FDA weight-management approval in the sources checked (mechanisms and sources).

Sources

All checked September 29, 2026. Trial and publication dates below are not the check date. Company results are attributed reports, not independent replications.

1. Eli Lilly. TRIUMPH-1 results. May 21, 2026.
2. Eli Lilly. TRIUMPH-2/3 results and FDA filing plan. July 23, 2026.
3. Eli Lilly. TRIUMPH-4 results. December 11, 2025.
4. Eli Lilly. Eloralintide Phase 2 results. November 6, 2025.
5. Novo Nordisk. CagriSema FDA filing. December 18, 2025.
6. Novo Nordisk. REDEFINE 1 results, Form 6-K. December 20, 2024.
7. Novo Nordisk. REIMAGINE 5/REDEFINE 9 results and FDA decision forecast. September 21, 2026.
8. Novo Nordisk. Annual Report 2025: innovation and therapeutic focus. 2025 reporting period.
9. Boehringer Ingelheim. SYNCHRONIZE-1 results. April 28, 2026.
10. Amgen. Phase 2 MariTide results and estimands. June 23, 2025.
11. Viking Therapeutics. Q2 results, VANQUISH and oral development. July 29, 2026.
12. Structure Therapeutics. ACCESS II results. March 16, 2026.
13. Structure Therapeutics. Q2 2026 financial results and first Phase 3 dosing. Q2 2026 update.
14. AstraZeneca. Elecoglipron VISTA results and Phase III program. June 8, 2026.
15. Pfizer. VESPER-3 28-week results. February 3, 2026.
16. Pfizer. Berobenatide development update. June 6, 2026.
17. Roche. CT-388/enicepatide Phase II results. January 27, 2026.
18. Hengrui and Kailera. GEMINI-1 China Phase 3 results. November 4, 2025.
19. Kailera. Q2 2026 results and oral/global plans. August 12, 2026.
20. Zealand Pharma. ZUPREME Phase 3 initiation. September 22, 2026.
21. Zealand Pharma. ZUPREME-1 results and estimands. Posted September 29, 2026 U.S. time; datelined September 30 in Denmark.
22. FDA. Foundayo approval. April 1, 2026.
23. Novo Nordisk. U.S. Wegovy pill approval. December 22, 2025.
24. FDA. Higher-dose Wegovy approval. March 19, 2026.
25. Rhythm. FDA approval of Imcivree for acquired hypothalamic obesity. March 19, 2026.
26. Rhythm. Q4/full-year 2025 results and bivamelagon plan. February 26, 2026.
27. Innovent. NMPA approval of mazdutide for weight management. June 27, 2025.
28. Sciwind. NMPA approval of ecnoglutide for weight management. March 6, 2026.
29. Aardvark. Quarterly SEC filing: HERO trial termination. Period ended June 30, 2026.
30. Chugai. Discontinuation of obesity development for emugrobart. September 28, 2026.
31. Original receptor research, Monash record. AM833/cagrilintide activity at calcitonin-family receptors. 2021.
32. Aphaia. Second Phase 2 obesity study. September 9, 2025.
33. FDA. Expanded access. Current guidance page.
34. FDA. Clinical research phases. Current explanatory page.
35. ClinicalTrials.gov. Glossary: dates and study status. Current registry definitions.
36. Becker's Hospital Review. Public pipeline-count page. 2026-09-02. Public stated count only; underlying paid data not recounted.
37. GoodRx. Public pipeline-count page. 2026-07-23 (page date); title checked 2026-09-29. Public stated count only; underlying paid data not recounted.
38. Expert Market Research. Public pipeline-count page. 2026 (report page). Public stated count only; underlying paid data not recounted.
39. IQVIA. Public pipeline-count page. 2026-02-19. Public stated count only; underlying paid data not recounted.
40. Ozmosi. Public pipeline-count page. 2026-08-17 (page date); checked 2026-09-29. Public stated count only; underlying paid data not recounted.
41. ResearchAndMarkets (GlobeNewswire release). Public pipeline-count page. 2026-09-23. Public stated count only; underlying paid data not recounted.
42. ClinicalTrials.gov. Exact selected-program query; individual record URLs in Table 9 and the trial CSV. Snapshot checked September 29, 2026.

GLP-1 Consumer Research is the research and reference section of Weight Loss Provider Guide.